Quality of Life and Health Economics Data: STAMPEDE Trial - Nick James
November 4, 2018
Nick James and Alicia Morgans discuss the quality of life and health economics data from the docetaxel part of the STAMPEDE trial. They also review data presented by Chris Parker on the use of radiotherapy to the primary tumor for men with newly-diagnosed metastatic prostate cancer.
Biographies:
Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR Senior Investigator, Consultant in Clinical Oncology at the Queen Elizabeth Hospital Birmingham and Professor of Clinical Oncology at the University of Birmingham.
Alicia Morgans, MD, MPH
Biographies:
Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR Senior Investigator, Consultant in Clinical Oncology at the Queen Elizabeth Hospital Birmingham and Professor of Clinical Oncology at the University of Birmingham.
Alicia Morgans, MD, MPH
Related Content:
Survival Results from STAMPEDE, Local Radiotherapy Improves Survival in Metastatic Prostate Cancer with Low Disease Burden
12-Year Follow-Up of GETUG-12, A Phase 3 Trial of Docetaxel-Based Chemotherapy in High-Risk Localized Prostate Cancer
Watch: A Clinical Conversation: CHAARTED, LATITUDE and STAMPEDE
Survival Results from STAMPEDE, Local Radiotherapy Improves Survival in Metastatic Prostate Cancer with Low Disease Burden
12-Year Follow-Up of GETUG-12, A Phase 3 Trial of Docetaxel-Based Chemotherapy in High-Risk Localized Prostate Cancer
Watch: A Clinical Conversation: CHAARTED, LATITUDE and STAMPEDE